Clinical Trials
32 trialsNCT00428142 2026-03-27
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT04915248 2025-12-24
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2 Recruiting
NCT01415752 2025-04-08
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT00030875 2023-08-04
Bortezomib in Treating Patients With Mantle Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT00377052 2023-08-04
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT01216683 2023-06-29
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00114738 2022-10-10
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00479167 2021-11-04
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Rush University Medical Center
Phase 2 Terminated
NCT01046006 2021-04-30
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
University of Athens
Phase 2 Completed
NCT00182637 2020-08-03
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00980395 2019-12-30
VCR
University of Arizona
Phase 2 Completed
NCT00439556 2019-09-10
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01848132 2018-09-19
Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT00376961 2017-11-06
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT01323920 2017-05-30
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01029730 2016-08-19
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00262860 2016-05-09
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
University of Rochester
Phase 2 Completed
NCT00740415 2016-03-16
ManteauRiBVD
French Innovative Leukemia Organisation
Phase 2 Completed
NCT00958256 2015-04-13
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00723658 2015-03-06
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00513955 2014-11-05
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
University Hospital Plymouth NHS Trust
Phase 2 Completed
NCT00851552 2014-07-21
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00217503 2013-06-20
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00045695 2013-05-17
Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00066508 2013-01-08
Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00093769 2012-10-04
Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00054665 2012-09-11
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00810576 2012-08-07
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00509379 2011-01-28
LYM-2023
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Phase 2 Completed
NCT00148018 2008-07-10
Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma
University of Cologne
Phase 2 Terminated
NCT00085696 2008-02-11
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00265928 2008-01-28
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated